GLP-1 Receptor Agonist Evidence: Beyond Obesity & Diabetes
The EVOKE trial investigates oral semaglutide cognitive outcomes in early Alzheimer’s disease. This GLP-1 receptor agonist evidence expands understanding beyond obesity and diabetes. Results inform clinical decisions on semaglutide’s neuroprotective…
A Health Technology Assessment of Medical Cannabis: Clinical and Economic Perspectives
Health technology assessment medical cannabis provides a rigorous evaluation of clinical efficacy and economic value. This assessment guides insurance coverage and formulary decisions. It represents a critical step toward integrating cannabis into…
What Does the Evidence Really Say About Cannabis Risks and Medical Benefits?
The cannabis health risks medical benefits evidence review 2024 synthesizes global research on recreational cannabis harms and medicinal benefits. It highlights adolescent vulnerability and modest medicinal efficacy. This review guides clinicians on…
